

ADULT AMBULATORY INFUSION ORDER 3/2023

Vedolizumab (ENTYVIO)

NAME:
BIRTHDATE:
INSURANCE:
PROVIDER NAME:
CLINIC NAME and Phone number:

Patient identification

W eight:	kg	H eight:	cm Allergies:	Diagnosis Code:
Treatme	ent Start Date	:		
**If trea	atment not st	arted within	90 days, new orders with	n updated date/signature will be required. Otherwise,
orders a	re valid for 1	year from si	gnature date.** GUIDELI	NES FOR ORDERING:
1)	Patient <u>nam</u>	e and date of	birth must be on EACH p	age of this order form. This form will be returned if any
	left blank.			
2)				E information. Send H&P or most recent chart note,
		nin the past 1		
3)	Send a copy	of related lal	results if not available for	or review in Epic.
Recomn	nended Pre-s	creening lab	s: Send results if not avail	able in Epic.
	Quantiferon			
			sion appointments: (selec	t all that apply)
	Quantiferon		•	
	Other:			
			lect all that apply)	
	-		L) tablet, 650 mg, oral, ev	•
		AMINE (BENA	ADRYL) tablet, 25 mg, oral	every visit.
MEDICA	_			
			_	e 0.9% 250 mL IVPB, over 30 Minutes.
	ALS: (must se			
	Induction &			
			6. After induction doses c	ompleted, continue treatment with maintenance doses
	every	_ weeks.		
	OR			
			•	vith ongoing maintenance orders. If Entyvio infusions
			of last infusion here:):
	-	week	S.	
	G ORDERS:			
√		•	•	fection or signs of active TB.
√	_		_	ce, and presence of infusion-related reactions prior to
		at the end o		
√		neral IV if no		
√			, ,	neparin injection for central line care.
√		•	• •	mporarily hold the infusion, and notify provider
	immediately	. include hyp	ersensitivity reaction ord	er set. (See attached form).

HYPERSENSITIVITY INFUSION REACTION ORDERS

STOP infusion if:

MILD REACTION: Localized pruritus, rhinitis, localized rash, fever greater than 38 degrees C.

- 1. Stop infusion and maintain IV access with NS line.
- 2. Notify MD of symptoms and infusion reaction orders initiated.

MODERATE REACTION: Generalized pruritus, generalized flushing, rash, back pain, mild dyspnea, chills, hypotension with SBP less than 90 mmHg or greater than 20% decrease in SBP.



Vedolizumab (ENTYVIO)

NAME:
BIRTHDATE:
INSURANCE:
PROVIDER NAME:
CLINIC NAME and Phone number:

Patient identification

- 1. Stop infusion, but do not discard infusion bag/bottle unless instructed by MD that therapy is to be discontinued.
 - 2. Maintain IV access with NS line.
 - 3. Place patients in a supine position with lower extremities elevated unless respiratory distress or nausea/vomiting.
 - 4. Maintain airway.

SEVERE REACTION: Respiratory distress (bronchospasm, stridor, wheezing, persistent cough, respiratory depression, cardiac arrhythmia, chest pain, generalized urticaria (hives), syncope, gastrointestinal symptoms (abdominal pain, N/V, diarrhea), hypotension SBP less than 80 mmHg, face/throat/tongue swelling, shock, loss of consciousness.

- 1. Stop infusion, but do not discard bag/bottle unless instructed by MD that therapy is to be discontinued.
- 2. Stay with patient and have another nurse notify MD of symptoms and infusion reaction orders initiated.
- 3. Place patients in supine position with lower extremities elevated unless respiratory distress or nausea/vomiting.
- 4. Maintain airway.
- 5. Maintain IV access with NS line.
- 6. Inpatients: Activate code blue for loss of blood pressure, pulse, or consciousness.

MEDICATIONS:

- Acetaminophen (TYLENOL) tablet 650 mg, Oral, EVERY 4 HOURS PRN, Pain, Other, Mild reaction. Starting when released.
- DiphenhydrAMINE (Benadryl) injection, 25 mg, Intravenous, EVERY 15 MIN PRN, Moderate or severe reaction, may repeat x1. Starting when released, For 2 doses.
- Methylprednisolone sodium succinate (solu-MEDROL) 62.5mg/ml injection, 125 mg, Intravenous, ONCE PRN, Severe reaction. Starting when released, For 1 dose. Mix with 2 mL provided diluent to make 62.5 mg/mL.
- Famotidine (PEPCID) injection 20 mg, Intravenous, ONCE PRN, Moderate reaction, or anaphylaxis, starting when released. Dilute 2 mL of famotidine with 8 mL of normal saline to a final concentration of 2 mg/mL. Administer ordered dose over a period of at least 2 minutes.
- Albuterol 90 mcg/puff inhaler 2 puff, Inhalation, ONCE PRN, Severe reaction p. Starting when released, For 1 dose. Shake well. Use with spacer.
- Start oxygen. For MODERATE Reaction: Start 2 liters O2 per nasal cannula as needed for SpO2 less than 93%. For SEVERE Reaction: Start continuous pulse oximetry. Administer 6 to 8 liters per minute (LPM) via face mask, or up to 100% oxygen to maintain oxygen saturation greater than 90%.
- EPINEPHrine 1 mg/mL injection 0.3 mg. Intramuscular, EVERY 5 MIN PRN, Anaphylaxis. Starting when released, For 3 doses. Administer in the anterior lateral thigh using 1 - 1.5-inch needle for airway obstruction symptoms and/or hypotension.
- Sodium chloride 0.9% (NS) infusion 500ml. At 500 mL/hr., Intravenous, PRN, Moderate reaction, or anaphylaxis. Starting when released. Run wide open to gravity.



ADULT AMBULATORY INFUSION ORDER
3/2023

Vedolizumab (ENTYVIO)

□ NEWBERG

NAME:
BIRTHDATE:
INSURANCE:
PROVIDER NAME:
CLINIC NAME and Phone number:

Patient identification

	the care of the patie	ent (who is identified at the top of this form).					
hold an active, unre	stricted license to p	ractice medicine in Oregon.					
	order infusion of th	and I am acting within my scope of practice and e medications and blood products described above for the patient					
Provider's printed na	ame:						
Date:							
Please complete the	following intake qu	uestions.					
Mobility status							
·	□ Independent						
	□ Walker						
□ Wheelchair							
☐ Fully depend	dent						
Bariatric needs							
☐ Yes, briefly describe							
□ No							
Transportation conc							
☐ Yes, briefly describe							
□ No							
nterpreter Service r	=						
☐ Yes, languag	□ Yes, language						
□ No							
Outpatient Infusion							
		e patient's preferred infusion center location:					
	ORTLAND	Phone- 503-215-6046 Fax- 503-487-3582					
	LLAMETTE FALLS						
	DFORD OD BIVER	Phone 541-732-7000 Fax- 541-732-3939					
_	OD RIVER	Phone 503 717 7650 Fay 503 470 3146					
□ SE/	ASIDE	Phone- 503-717-7650 Fax- 503-470-3146					

Phone-**503-537-6040** Fax-**503-205-8720**